NEWS

NEWS

Company News

Industry News

2026-01-21

Yichang Tianrui Biopharm Reaches Critical Milestone: Letermovir API Awarded "I" Status by China CDE, GMP Certification Imminent

Yichang Tianrui Biopharm Reaches Critical Milestone: Letermovir API Awarded "I" Status by China CDE, GMP Certification Imminent

MORE

2026-01-21

Yichang Tianrui Biopharm Achieves Major Milestone: Granisetron API Successfully Filed in CDE with "I" Status, Paving the Way for Swift GMP Approval

Yichang Tianrui Biopharm Achieves Major Milestone: Granisetron API Successfully Filed in CDE with "I" Status, Paving the Way for Swift GMP Approval

MORE

2026-01-21

Yichang Tianrui Biopharm Achieves Key Regulatory Milestone: Landiolol Hydrochloride API Receives "I" Status from China's CDE

Yichang Tianrui Biopharm Achieves Key Regulatory Milestone: Landiolol Hydrochloride API Receives "I" Status from China's CDE

MORE

Yichang Tianrui Biopharm Achieves Major Milestone: Maribavir API Assigned "I" Status in China's CDE, GMP Certification Imminent

Yichang Tianrui Biopharm Achieves Major Milestone: Maribavir API Assigned "I" Status in China's CDE, GMP Certification Imminent

21

2026/01

Yichang Tianrui Biopharm Secures CDE “I” Designation for Baricitinib API – GMP Certification Imminent, Global Supply Ready

Yichang Tianrui Biopharm Secures CDE “I” Designation for Baricitinib API – GMP Certification Imminent, Global Supply Ready

21

2026/01

Samidorphan L-Malate API – Precision-Built for Next-Generation Psychiatric Therapies

Samidorphan L-Malate API – Precision-Built for Next-Generation Psychiatric Therapies

14

2026/01

Pioneering Achievement! Yichang Tianrui's Osimertinib Mesylate Secures Breakthrough Status, Leading the Future of High-End Pharmaceutical APIs

Pioneering Achievement! Yichang Tianrui's Osimertinib Mesylate Secures Breakthrough Status, Leading the Future of High-End Pharmaceutical APIs

high quality API-Osimertinib Mesylate

11

2025/12

Exhibition Summary Report: Yichang Tianrui Biopharm Co., Ltd successful attented CPHI Frankurt 2025

Exhibition Summary Report: Yichang Tianrui Biopharm Co., Ltd successful attented CPHI Frankurt 2025

10

2025/11

Yichang Tianrui Biopharm Secures CDE “I” Status for Fosaprepitant Dimeglumine API – GMP Certificate Expected Within Weeks, Global Launch Capacity Ready

Yichang Tianrui Biopharm Secures CDE “I” Status for Fosaprepitant Dimeglumine API – GMP Certificate Expected Within Weeks, Global Launch Capacity Ready

21

2026/01

Yichang Tianrui Biopharm Secures CDE “I” Status for Enzalutamide API – GMP Certification Imminent, Global Supply Chain Ready

Yichang Tianrui Biopharm Secures CDE “I” Status for Enzalutamide API – GMP Certification Imminent, Global Supply Chain Ready

21

2026/01

Yichang Renfu has been successfully included in the Hubei Province 2025 5G Factory List.

Yichang Renfu has been successfully included in the Hubei Province 2025 5G Factory List.

The Hubei Provincial Department of Economy and Information Technology officially released the 2025 5G Factory Directory, and the “Yichang Renfu 5G Smart Factory” project was smoothly selected.

12

2025/12